Thursday, November 12, 2026

Cocoa Futures Drops By 8% In The Last 21 Sessions

Cocoa Futures Drops By 8% In The Last 21 Sessions

(VIANEWS) - Cocoa (CC) has been up by 8.97% for the last 21 sessions. At 05:51 EST on Monday, 22 July, Cocoa (CC) is $7,806.00.

Volume

Today's last reported volume for Cocoa is 828, 99.99% below its average volume of 9721852.64.

Volatility

Cocoa's last week, last month's, and last quarter's current intraday variation average was a negative 0.29%, a positive 0.82%, and a positive 1.83%, respectively.

Cocoa's highest amplitude of average volatility was 2.15% (last week), 1.65% (last month), and 1.83% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Cocoa's commodity is considered to be oversold (<=20).

News about

  • According to FXStreet on Monday, 22 July, "Meanwhile, concerns about an economic slowdown in China - the world's top oil importer - should act as a headwind for Crude Oil prices. ", "This assists Crude Oil prices in reversing a part of Friday's heavy losses to a one-month low, underpinning the commodity-linked Loonie and contributing to keeping a lid on the USD/CAD pair."
  • According to FXStreet on Monday, 22 July, "This, in turn, is seen lending some support to the USD-denominated commodities, including Crude Oil prices.", "This, along with China's economic woes, should keep a lid on any meaningful upside for Crude Oil prices."

More news about Cocoa (CC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com